Astrazeneca Share News (AZN)

UK BROKER RATINGS: UBS Raises Randgold Resources To Buy From Neutral

UK MORNING BRIEFING: London Shares Slide At Open On Eurozone Worries

Scientists find lung cancer can lie hidden for 20 years

* Disease evolves over many years along multiple pathways * Diversity helps explain why disease so hard to treat * Research highlights need for earlier detection By Ben Hirschler LONDON, Oct 9 (Reuters) - Lung cancer can lie dormant for more than 20 years before turning de

BUZZ-Innate Pharma: Citi lauds French biotech firm's cancer work

** Shares in French biotechnology company Innate Pharma jump 8 pct as Citi initiates with a "buy" recommendation and 10 euros/share PT. ** French biotech this year: http://link.reuters.com/kag23w ** Innate tipped as a rarity in Europe -- a publicly listed immuno-oncology company with

Woodford sells stake in Reckitt Benckiser

Woodford Investment Management has added to its core holdings in British American Tobacco and G4S in its portfolio but announced it had sold down its stake in Reckitt Benckiser. Speaking about its decision to sell stakes in the multinational consumer goods company, which had been part of the fund fo

London midday: Mining gains offset by falls from airline, healthcare stocks

Poor economic data was weighing on UK stocks on Tuesday, with decent gains in the mining sector offset by falls from airlines and pharmaceuticals. The FTSE 100 was trading 0.6% lower at 6,522 by around midday. Nervousness ahead of the start of third-quarter earnings season in the States was also ca

Tuesday broker round-up UPDATE

African Minerals: Canaccord Genuity lowers target price from 20p to 15p with a hold recommendation. Aggreko: Exane initiates with a target price of 1500p and an underperform rating. Amec: Liberum Capital cuts target price from 1035p to 908p staying with its sell recommendation. Antofagasta: Canacc

UK BROKER RATINGS: Merrill Lynch Cuts Schroders To Underperform

London open: UK stocks drop despite mining gains

Strong gains in the UK mining sector weren't enough to keep London's FTSE 100 from slipping into the red on Tuesday morning. Indices across Europe were tracking a weak finish on Wall Street and a mixed performance on Asian markets overnight. The FTSE 100 was trading 0.6% lower at 6,526 within the o

AstraZeneca heart drug gets preferred status in U.S.

LONDON, Oct 6 (Reuters) - AstraZeneca's blood-thinning drug Brilinta has won preferred status in the United States, where two medical groups have recommended it over the older drug Plavix, also known as clopidogrel. The endorsement comes in an updated guideline from the American Heart Asso

UPDATE 2-Becton Dickinson to buy CareFusion for $12 bln in cash, stock

(Adds details, background) By Deena Beasley Oct 5 (Reuters) - Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar healthcar

UPDATE 1-Becton Dickinson to buy CareFusion for $12 bln in cash, stock

(Adds background, CEO comments) By Deena Beasley Oct 5 (Reuters) - Medical equipment supplier Becton Dickinson & Co has agreed to buy CareFusion Corp , a maker of infusion pumps and other medical devices, for $12.2 billion in cash and stock, marking the latest multibillion-dollar heal

BUZZ-BTG Group: top-ten shareholder adding to stake

** Eighth-largest shareholder Axa Investment Managers adding to stake in biotech firm BTG Group, backing stock to enter FTSE 100. ** Nigel Thomas, manager of the £4.5 bln Axa Framlington UK Select Opportunities fund, increasing the fund's exposure to healthcare through BTG and AstraZeneca.

UPDATE 1-Esperion drug succeeds in lowering LDL cholesterol -study

(Adds share move, analyst forecast) By Bill Berkrot Oct 1 (Reuters) - An experimental cholesterol-fighting drug being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, Esperion said on Wednesday.

Esperion drug succeeds in lowering LDL cholesterol -study

By Bill Berkrot Oct 1 (Reuters) - A new type of experimental cholesterol fighter being developed by Esperion Therapeutics Inc lowered LDL levels significantly more than Merck & Co Inc's Zetia in a midstage clinical trial, the company said on Wednesday. In the 12-week study involving